UNITED STATES RHEUMATOLOGY PRACTICE BASED REAL-WORLD EVIDENCE OF METHOTREXATE UTILIZATION AND RESPONSE TO THERAPY IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH INTRAVENOUS GOLIMUMAB: 52-WEEK FROM THE AWARE STUDY

被引：0

作者：

Broadwell, Aaron ^{[1
]}

Schechtman, Joy ^{[2
]}

Conaway, Douglas ^{[3
]}

Kivitz, Alan ^{[4
]}

Black, Shawn ^{[5
]}

Xu, Stephen ^{[6
]}

Langholff, Wayne ^{[6
]}

Zazzetti, Federico ^{[7
]}

Kafka, Shelly ^{[5
]}

机构：

[1] Rheumatol & Osteoporosis Specialists, Shreveport, LA USA

[2] SunValley Arthrit Ctr, Peoria, IL USA

[3] Grand Strand Reg Med, Myrtle Beach, SC USA

[4] Altoona Ctr Clin Res, Duncansville, PA USA

[5] Janssen Sci Affairs LLG, Horsham, PA USA

[6] Janssen Res & Dev LLC, Spring House, PA USA

[7] Janssen LATAM Med Affairs, Buenos Aires, DF, Argentina

来源：

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2020年 / 26卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

132

引用

页码：82 / 82

页数：1

共 36 条

[31] Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study
Andrew Östör
Eugen Feist
Prodromos Sidiropoulos
Jérôme Avouac
Martin Rebella
Rajaie Namas
Erin McDearmon-Blondell
Tianming Gao
Ivan Lagunes-Galindo
Sander Strengholt
Devy Zisman
Suzan Attar
Arthritis Research & Therapy, 27 (1)
[32] Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy
Wei, Wenhui
Knapp, Keith
Wang, Li
Chen, Chieh-I
Craig, Gary L.
Ferguson, Karen
Schwartzman, Sergio
ADVANCES IN THERAPY, 2017, 34 (08) : 1936 - 1952
[33] Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy
Wenhui Wei
Keith Knapp
Li Wang
Chieh-I Chen
Gary L. Craig
Karen Ferguson
Sergio Schwartzman
Advances in Therapy, 2017, 34 : 1936 - 1952
[34] The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study
Moots, Robert J.
Xavier, Ricardo M.
Mok, Chi Chiu
Rahman, Mahboob U.
Tsai, Wen-Chan
Al-Maini, Mustafa H.
Pavelka, Karel
Mahgoub, Ehab
Kotak, Sameer
Korth-Bradley, Joan
Pedersen, Ron
Mele, Linda
Shen, Qi
Vlahos, Bonnie
PLOS ONE, 2017, 12 (04):
[35] The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study (vol 12, e0175207, 2017)
Moots, Robert J.
Xavier, Ricardo M.
Mok, Chi Chiu
Rahman, Mahboob U.
Tsai, Wen-Chan
Al-Maini, Mustafa H.
Pavelka, Karel
Mahgoub, Ehab
Kotak, Sameer
Korth-Bradley, Joan
Pedersen, Ron
Mele, Linda
Shen, Qi
Vlahos, Bonnie
PLOS ONE, 2017, 12 (06):
[36] Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy Increases the Feasibility of Long-Term PI Treatment and Benefit for Newly Diagnosed Multiple Myeloma (NDMM) Patients in an Outpatient Setting: Updated Real-World Results from the Community-Based United States (US) MM-6 Study
Girnius, Saulius K.
Yimer, Habte A.
Noga, Stephen J.
Manda, Sudhir
Lyons, Roger M.
Bogard, Kimberly
Whidden, Presley
Cherepanov, Dasha
Lu, Vickie
Aiello, Jack
Richter, Joshua R.
Rifkin, Robert M.
BLOOD, 2020, 136

← 1 2 3 4 →